Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials

Set Alert for Clinical Trials

J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints

If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.

Commercial Clinical Trials

DBV Soars As Path For Peanut Allergy Patch Approval Clears

The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.

Immune Disorders Drug Review

Genmab/AbbVie’s Epcoritamab Advances As Deal Bears Fruit

The Danish company pockets $40m as the lead asset in the potential multi-billion dollar deal with AbbVie for bi-specific antibodies progresses into Phase III, and while it looks to build up its commercial infrastructure.

Clinical Trials Cancer

Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up

Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.

Coronavirus COVID-19 Companies

An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.

Clinical Trials Neurology

Research Preprints: Pharma’s Slow Embrace And Predicament

Pharma appears to be treading carefully when it comes to research preprints but COVID-19 has spotlighted the role of these pre-peer-reviewed papers during public health emergencies.

Research & Development Clinical Trials

Lilly Sees Positive Results With Next-Gen Alzheimer’s Drug Donanemab

Lilly reported positive results from a Phase II pivotal trial of donanemab, which targets a modified form of beta-amyloid called N3pG, and has a second pivotal Phase II study under way.

Clinical Trials Neurology

Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19

After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.

Companies Commercial

Sarepta Sinks On Mixed DMD Gene Therapy Study

Any time advantage Sarepta's Duchenne muscular dystrophy gene therapy may have had over rivals, notably Pfizer, has disappeared after SRP-9001 failed to significantly improve muscle function in a closely watched trial.

Gene Therapy Clinical Trials
See All
UsernamePublicRestriction

Register